查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924649

诊断放射性药物市场（依产品类型、放射性核种、应用、最终用途及通路划分）－2026-2032年全球预测

Diagnostic Radiopharmaceuticals Market by Product Type, Radionuclide, Application, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，诊断放射性药物市场价值将达到 32.8 亿美元，到 2026 年将成长至 35.7 亿美元，到 2032 年将达到 64 亿美元，年复合成长率为 10.01%。

关键市场统计数据
基准年 2025 32.8亿美元
预计年份：2026年 35.7亿美元
预测年份 2032 64亿美元
复合年增长率 (%) 10.01%

这是一份经营团队和临床医生的策略指南，说明现代诊断放射性药物、技术融合、临床驱动因素和营运重点。

随着分子成像技术的进步、监管环境的日益清晰以及供应链的现代化，诊断放射性药物产业正在迅速发展，并重塑临床实践。本导言为需要对当前产业环境及其即将到来的转折点进行综合性、循证理解的经营团队、临床医生和投资者提供了清晰易懂的指导。它重点阐述了示踪剂创新、影像平台功能以及伴随诊断在实现精准医疗中日益重要的作用之间的相互作用。

技术创新、监管政策的明确性以及营运整合如何共同改变分子影像示踪剂的效用、临床工作流程和商业化路径

诊断放射性药物领域正经历一场变革浪潮，其驱动力来自技术创新、监管成熟和不断变化的临床需求。新型PET示踪剂具有更高的特异性和更长的效用寿命，能够更精确地表征病灶并进行治疗分层。同时，迴旋加速器的普及和发生器技术的同步进步正在提升医疗机构的自主生产能力。因此，投资于整合影像工作流程和放射化学专业知识的医疗机构更有能力缩短诊断时间，并充分发挥分子影像的临床价值。

评估关税带来的成本压力对2025年前营运和采购的影响，并探讨各组织如何调整其采购、生产和库存策略。

关税的累积影响将持续到2025年，对诊断放射性药物产业的生产和分销经济造成了显着压力。进口原料、专用组件和某些放射性核种产生器的关税成本上涨，促使相关人员重新评估其筹资策略和库存管理实务。为此，一些製造商尽可能在地采购，而另一些製造商则透过供应商多元化和重新谈判供应合约来缓解利润率下降。

详细的細項分析揭示了产品类型、临床应用、放射性核素特性、最终用途环境和分销选择如何影响采用趋势和营运风险。

细分市场层面的洞察凸显了临床需求、生产复杂性和商业性机会在产品-应用-放射性核种-最终用途-通路等各个维度上的交汇点。在产品类型方面，PET和SPECT放射性药物的差异决定了不同的研发路径和物流需求。在PET放射性药物中，碳-11、氟-18和镓-68的半衰期和生产规模各不相同，这会影响它们在临床应用方面的可行性。同时，在SPECT放射性药物中，碘-123、Technetium-99m和铊-201具有传统的临床应用价值和成熟的供应链，这影响着人们对这些放射性药物的采纳和替代风险的评估。

区域比较评估概述了关键区域的基础设施、监管差异和分销物流如何影响临床应用和商业化方法。

区域趋势受临床能力、法规结构和供应链结构等因素的共同影响，进而影响诊断放射性药物的地域覆盖范围和商业化进程。在美洲，完善的核子医学基础设施、密集的学术医疗中心以及较为宽鬆的支付环境，有利于新型示踪剂的快速临床应用。然而，区域报销政策的差异和物流距离的差异，造成了营运上的细微差别，需要根据区域特征制定相应的分销和服务模式。

企业策略要务将示踪剂创新、生产柔软性和协作商业化模式结合，以确保临床应用和持续的市场进入。

公司层级的考量主要集中在研发重点、製造地和商业伙伴关係方面的策略选择将如何决定其竞争地位。主要企业正投资于示踪剂研发管线，优先考虑临床差异化、可重复的生产流程以及支援集中式和分散式供应模式的模组化生产能力。这些企业正将示踪剂的开发与强有力的临床证据生成和相关人员参与计划相结合，以增强临床效用并促进医保报销谈判。

为加强生产韧性、临床支援以及建立生态系统伙伴关係以推动应用并确保业务永续营运连续性，提出切实可行的建议

产业领导者应在控製成本的同时，优先考虑供应链韧性、临床整合和实证医学证据的产生。首先，扩大灵活的生产能力并实现原材料和来源多元化，可以降低贸易中断和关税波动带来的风险，并能够快速回应不断变化的临床需求。其次，将示踪剂的应用与切实可行的临床支持项目（标准化的影像通讯协定、放射科医生培训以及强调临床终点的医保支付材料）相结合，可以加快示踪剂在临床环境中的应用，并明确报销流程。

一种透明、以证据为导向的调查方法，结合相关人员访谈、临床文献综合和供应链营运分析，将策略洞见与实际情况结合。

本分析的调查方法结合了系统性文献综述、针对性相关人员访谈以及对临床和营运证据的结构化综合分析。主要定性资料来自对核子医学医师、放射性药物药剂师、供应链管理人员和监管专家的访谈，以确保能够捕捉实际实施中的挑战和临床决策的决定因素。这些见解与同行评审文章、监管指导文件和行业技术简报进行三角验证，检验临床结论并阐明营运限制。

透过整体整合，将示踪剂创新、营运准备和策略商业化连结起来，以推动临床影响和在医疗保健领域的永续应用。

总之，诊断放射性药物处于科学进步与实际应用的交汇点，示踪剂的创新必须与生产的灵活性、临床教育和强大的分销网络相辅相成。最成功的措施将预见物流限制，投资于严谨的临床证据，并设计符合诊断影像中心、医院和研究机构实际情况的商业化模式。监管政策的明确和数位成像技术的进步，加上确凿的价值证明，将促进其进一步的规模化应用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 诊断放射性药物市场（依产品类型划分）

  • PET放射性药物
  • SPECT放射性药物

9. 依放射性核种类型分類的诊断放射性药物市场

  • 氟-18
  • 镓-68
  • 碘-123
  • Technetium-99m

第十章 按应用分類的诊断放射性药物市场

  • 心臟病学
    • 灌注影像
    • 可行性成像
  • 神经病学
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 乳癌
    • 肺癌
    • 摄护腺癌

第十一章 以最终用途分類的诊断放射性药物市场

  • 诊断影像中心
  • 医院
  • 研究所

第十二章 诊断放射性药物市场（依分销管道划分）

  • 离线
  • 在线的

第十三章 区域诊断放射性药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 诊断放射性药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国诊断放射性药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国诊断放射性药物市场

第十七章：中国诊断放射性药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actinium Pharmaceuticals Inc
  • Advanced Accelerator Applications SA
  • Bayer AG
  • Bracco Imaging SpA
  • BWXT Medical Ltd
  • Cardinal Health
  • China Isotope & Radiation Corporation
  • Clarity Pharmaceuticals Pty Ltd
  • Curium Pharma
  • Eckert & Ziegler AG
  • Eli Lilly and Company
  • GE Healthcare
  • Imagen Clinical Ltd
  • Isologic Innovative Radiopharmaceuticals Ltd
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings Inc
  • Nordion Inc
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • Oncoinvent AS
  • RadioMedix Inc
  • Radiopharm Theranostics Ltd
  • Siemens Healthineers
  • Telix Pharmaceuticals Ltd
Product Code: MRR-7A380DA7C3FA

The Diagnostic Radiopharmaceuticals Market was valued at USD 3.28 billion in 2025 and is projected to grow to USD 3.57 billion in 2026, with a CAGR of 10.01%, reaching USD 6.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.28 billion
Estimated Year [2026] USD 3.57 billion
Forecast Year [2032] USD 6.40 billion
CAGR (%) 10.01%

A strategic orientation to contemporary diagnostic radiopharmaceuticals that explains technological convergence, clinical drivers, and operational priorities for executives and clinicians

The diagnostic radiopharmaceuticals landscape is undergoing rapid evolution as advances in molecular imaging, regulatory clarity, and supply chain modernization converge to reshape clinical practice. This introduction provides a clear, accessible orientation for executives, clinicians, and investors who require an evidence-based synthesis of the current environment and its near-term inflection points. It highlights the interplay between tracer innovation, imaging platform capabilities, and the growing role of companion diagnostics in enabling precision medicine pathways.

Readers will find a concise framing of the technologies, clinical use-cases, and stakeholder incentives that drive demand for PET and SPECT agents across diagnostic applications. The narrative emphasizes practical considerations such as production logistics, radionuclide half-life management, and integration with imaging infrastructure, while drawing attention to regulatory and reimbursement factors that influence adoption trajectories. By establishing this baseline, the introduction sets the stage for deeper analysis of structural shifts, tariff-driven cost dynamics, and segment-specific strategic implications.

How technological innovation, regulatory clarity, and operational integration are jointly transforming tracer utility, clinical workflows, and commercialization pathways in molecular imaging

The field of diagnostic radiopharmaceuticals is experiencing transformative shifts driven by confluence of technological innovation, regulatory maturation, and changing clinical demand. Novel PET tracers with improved specificity and longer utility windows are enabling more precise lesion characterization and treatment stratification, while parallel improvements in cyclotron access and generator technologies are expanding on-site production capabilities. Consequently, institutions that invest in integrated imaging workflows and radiochemistry expertise are positioned to shorten time-to-diagnosis and to capture the clinical value of molecular imaging.

Regulatory agencies are increasingly providing clearer pathways for tracer approval and for companion diagnostic claims, which reduces procedural ambiguity for sponsors and accelerates clinical translation. Meanwhile, digital imaging analytics and AI-driven quantification enhance interpretive consistency and permit more efficient utilization of imaging assets. Taken together, these dynamics are reshaping procurement priorities, clinical protocols, and partnership models across suppliers, academic centers, and diagnostic networks, and they highlight the need for iterative alignment between product development and health-system operational readiness.

Assessing the operational and procurement implications of tariff-driven cost pressures through 2025 and how organizations are adapting sourcing, production, and inventory strategies

The cumulative effects of tariff actions enacted through 2025 have introduced measurable pressure on manufacturing and distribution economics within the diagnostic radiopharmaceutical sector. Tariff-induced cost increases for imported raw materials, specialized components, and select radionuclide generators have encouraged stakeholders to re-evaluate sourcing strategies and inventory practices. In response, some manufacturers have localized critical inputs where feasible, while others have pursued supplier diversification and renegotiated supply contracts to mitigate margin compression.

Across clinical providers, elevated input costs have driven more disciplined purchasing and an increased focus on operational efficiency, including dose optimization and scheduling strategies that reduce waste from short-lived isotopes. Regulatory compliance and cold-chain integrity remain non-negotiable, so organizations have balanced cost containment with the need to preserve quality and patient safety. Importantly, tariff impacts have also accelerated conversations around domestic production capacity and public-private partnerships that can reduce exposure to cross-border trade variability. Looking forward, institutions will likely continue to adapt procurement models and contractual structures to enhance resilience amid evolving trade policy landscapes.

Deep segmentation analysis revealing how product type, clinical application, radionuclide profile, end-use setting, and distribution choices shape adoption dynamics and operational risks

Segment-level insights clarify where clinical demand, production complexity, and commercial opportunity intersect across product, application, radionuclide, end-use, and distribution vectors. Based on Product Type, the distinction between PET Radiopharmaceuticals and SPECT Radiopharmaceuticals frames divergent development pathways and logistical requirements; within PET Radiopharmaceuticals, Carbon-11, Fluorine-18, and Gallium-68 represent varying half-lives and production footprints that influence site-of-care feasibility, while within SPECT Radiopharmaceuticals, Iodine-123, Technetium-99m, and Thallium-201 carry legacy clinical roles and established supply chains that inform adoption and substitution risks.

Based on Application, clinical segmentation across Cardiology, Neurology, and Oncology highlights differing clinical workflows and payer dynamics; cardiology use-cases such as Perfusion Imaging and Viability Imaging require high-throughput protocols and rapid tracer availability, neurology indications focused on Alzheimer's and Parkinson's necessitate high specificity and longitudinal imaging consistency, and oncology applications across Breast Cancer, Lung Cancer, and Prostate Cancer demand tracers that support staging, recurrence detection, and therapy selection. Based on Radionuclide, the prominence of Fluorine-18, Gallium-68, Iodine-123, and Technetium-99m delineates supply chain and half-life management priorities. Based on End Use, Diagnostic Imaging Centers, Hospitals, and Research Institutes each exhibit distinct capital investment profiles and regulatory oversight that shape adoption timing and partnership opportunities. Based on Distribution Channel, Direct Sales, Distributors, and Online Channels create different customer engagement models and service-level expectations, which in turn influence margin structures and post-sale support requirements.

These layered segmentations underscore the necessity of aligning product development with practical constraints such as isotopic half-life, on-site production capacity, and clinical throughput. Consequently, organizations with adaptable manufacturing, robust distribution agreements, and clinical support services are best positioned to capitalize on cross-segment synergies while managing operational complexity.

Comparative regional assessment that outlines how infrastructure, regulatory diversity, and distribution logistics shape clinical uptake and commercialization approaches across key territories

Regional dynamics reflect a combination of clinical capacity, regulatory frameworks, and supply chain architecture that influence where diagnostic radiopharmaceuticals gain traction and how they are commercialized. In the Americas, established nuclear medicine infrastructure, a concentration of academic medical centers, and a receptive payer environment support rapid clinical translation of novel tracers, but regional reimbursement variability and logistical distances present operational nuances that require tailored distribution and service models.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and varied healthcare financing mechanisms necessitate a regionally nuanced go-to-market strategy that accounts for national certification frameworks and differing levels of cyclotron access, while collaborative cross-border research and consortium-based procurement offer pathways to scale. In Asia-Pacific, rapid investment in diagnostic imaging capacity, growing oncology care demand, and expanding manufacturing capabilities have created fertile conditions for both local production and international partnerships, although procurement processes and regulatory timelines vary widely between markets. Across all regions, proximity to production sites, robustness of cold-chain logistics, and clinician familiarity with novel tracers will determine the pace and pattern of clinical adoption, underscoring the importance of region-specific commercialization plans that reflect local operational realities.

Strategic company imperatives that align tracer innovation, production flexibility, and collaborative commercialization models to secure clinical adoption and durable market access

Company-level considerations focus on how strategic choices in R&D focus, manufacturing footprint, and commercial partnerships determine competitive positioning. Leading organizations are investing in tracer pipelines that prioritize clinical differentiation, reproducible manufacturing processes, and modular production capacity to support both centralized and decentralized supply models. These firms are coupling tracer development with robust clinical evidence generation and stakeholder engagement programs to reinforce clinical utility and to smooth reimbursement dialogues.

Across the ecosystem, smaller specialized players are leveraging nimble development cycles and targeted clinical collaborations to establish early clinical proof points, while larger diversified suppliers are integrating radiopharmaceuticals into broader diagnostic portfolios and leveraging global distribution networks. Strategic alliances between manufacturers, imaging equipment providers, and clinical research organizations are also becoming more common as firms seek to lower barriers to adoption through bundled solutions that address tracer availability, imaging protocols, and interpretive support. Ultimately, companies that balance scientific rigor with pragmatic operational solutions and proactive regulatory engagement will achieve the most durable market access and clinical integration.

Actionable recommendations for bolstering production resilience, clinical support, and ecosystem partnerships to accelerate adoption and safeguard operational continuity

Industry leaders should prioritize investments that strengthen supply chain resilience, clinical integration, and evidence generation while maintaining cost discipline. First, expanding flexible production capacity and diversifying raw material and generator sourcing reduces exposure to trade disruptions and tariff volatility, and it enables faster response to clinical demand shifts. Second, coupling tracer launches with pragmatic clinical support programs-standardized imaging protocols, education for interpreting physicians, and payer-facing dossiers that emphasize clinical endpoints-will accelerate institutional uptake and reimbursement clarity.

Third, forging partnerships across the imaging ecosystem, including imaging device manufacturers, research hospitals, and specialty distributors, will facilitate bundled proposition development that reduces the operational burden on adopters. Fourth, leaders should adopt digital and AI-enabled tools to improve quantitative imaging reproducibility and to extract real-world evidence from routine clinical use; such data strengthen value propositions and support iterative improvements. Finally, organizations should adopt a modular commercialization approach that customizes distribution and service models for Diagnostic Imaging Centers, Hospitals, and Research Institutes, thereby aligning price, service, and compliance expectations with end-user capabilities and procurement preferences.

Transparent, evidence-focused methodology combining stakeholder interviews, clinical literature synthesis, and operational supply chain analysis to ground strategic insights in practical realities

The methodology underpinning this analysis combined systematic literature review, targeted stakeholder interviews, and a structured synthesis of clinical and operational evidence. Primary qualitative inputs were drawn from interviews with practicing nuclear medicine physicians, radiopharmacists, supply chain managers, and regulatory specialists, ensuring that practical implementation challenges and clinical decision drivers were captured. These perspectives were triangulated with peer-reviewed publications, regulatory guidance documents, and industry technical briefs to validate clinical claims and to contextualize operational constraints.

Analysts applied a cross-sectional lens to segment performance, mapping tracer attributes-such as radionuclide half-life, synthesis complexity, and imaging protocol requirements-to end-user capabilities and distribution modalities. Where appropriate, supply chain analyses examined manufacturing footprints, generator and cyclotron dependencies, and cold-chain requirements to assess operational feasibility. Throughout, the approach favored transparency in assumptions and prioritized evidence that directly informs clinical utility, regulatory readiness, and operational execution.

Concluding synthesis that links tracer innovation, operational readiness, and strategic commercialization to drive clinical impact and sustainable adoption across care settings

In conclusion, diagnostic radiopharmaceuticals stand at the intersection of scientific progress and operational pragmatism, where tracer innovation must be matched by production agility, clinical education, and resilient distribution. The most successful initiatives will be those that anticipate logistical constraints, invest in rigorous clinical evidence, and design commercialization models that align with the realities of Diagnostic Imaging Centers, Hospitals, and Research Institutes. Regulatory clarity and digital imaging advances will further enable scalable adoption when linked to robust value demonstrations.

As institutions and suppliers adapt to tariff pressures, evolving procurement practices, and region-specific considerations, strategic emphasis on supply diversification, clinical support services, and collaborative commercialization will determine how rapidly novel tracers translate into improved diagnostic pathways. Stakeholders who integrate these considerations into product development and market entry strategies will be better equipped to deliver clinical impact while managing operational and commercial risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diagnostic Radiopharmaceuticals Market, by Product Type

  • 8.1. PET Radiopharmaceuticals
  • 8.2. SPECT Radiopharmaceuticals

9. Diagnostic Radiopharmaceuticals Market, by Radionuclide

  • 9.1. Fluorine-18
  • 9.2. Gallium-68
  • 9.3. Iodine-123
  • 9.4. Technetium-99m

10. Diagnostic Radiopharmaceuticals Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Perfusion Imaging
    • 10.1.2. Viability Imaging
  • 10.2. Neurology
    • 10.2.1. Alzheimer's
    • 10.2.2. Parkinson's
  • 10.3. Oncology
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Prostate Cancer

11. Diagnostic Radiopharmaceuticals Market, by End Use

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Diagnostic Radiopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Diagnostic Radiopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Diagnostic Radiopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Diagnostic Radiopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Diagnostic Radiopharmaceuticals Market

17. China Diagnostic Radiopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actinium Pharmaceuticals Inc
  • 18.6. Advanced Accelerator Applications SA
  • 18.7. Bayer AG
  • 18.8. Bracco Imaging S.p.A.
  • 18.9. BWXT Medical Ltd
  • 18.10. Cardinal Health
  • 18.11. China Isotope & Radiation Corporation
  • 18.12. Clarity Pharmaceuticals Pty Ltd
  • 18.13. Curium Pharma
  • 18.14. Eckert & Ziegler AG
  • 18.15. Eli Lilly and Company
  • 18.16. GE Healthcare
  • 18.17. Imagen Clinical Ltd
  • 18.18. Isologic Innovative Radiopharmaceuticals Ltd
  • 18.19. ITM Isotope Technologies Munich SE
  • 18.20. Jubilant Pharmova Limited
  • 18.21. Lantheus Holdings Inc
  • 18.22. Nordion Inc
  • 18.23. NorthStar Medical Radioisotopes LLC
  • 18.24. Novartis AG
  • 18.25. Oncoinvent AS
  • 18.26. RadioMedix Inc
  • 18.27. Radiopharm Theranostics Ltd
  • 18.28. Siemens Healthineers
  • 18.29. Telix Pharmaceuticals Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-123, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-123, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-123, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PERFUSION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PERFUSION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PERFUSION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY VIABILITY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY VIABILITY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY VIABILITY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMER'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMER'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMER'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PARKINSON'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PARKINSON'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PARKINSON'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)